Literature DB >> 9298419

Phacoemulsification at King Khaled Eye Specialist Hospital--the experience of the past.

K D Teichmann1, A A al-Rajhi, M H Jabak, S R Antonios, S Haddab, S D Smith.   

Abstract

OBJECTIVE: To study the outcome of phacoemulsification (PE) compared to standard extracapsular surgery before the introduction of state-of-the-art techniques (capsulorhexis, hydrodissection, nuclear cracking, nuclear chopping, sutureless incisions) and sophisticated equipment. STUDY
DESIGN: Charts from 375 patients (453 eyes) undergoing PE between 1984 and 1989 were randomly selected and studied retrospectively. A minimum age of 35 years, and a minimum follow-up of three months were required.
SETTING: A large eye hospital in the Kingdom of Saudi Arabia staffed with an international faculty of ophthalmic surgeons. PATIENTS: Patients over 35 years of age undergoing PE for immature, mature and traumatic cataract. MAIN OUTCOME MEASURES: Postoperative visual acuity, and rate or frequency of intraoperative complications.
RESULTS: 66.5% achieved visual acuity of 20/40 or better, which compares favourably with the 36.5% of eyes reaching this level of visual acuity after mainly standard extracapsular cataract surgery in another study at our hospital. Posterior capsule ruptures occurred in 7.5% and vitreous loss in 5.5%. Other ocular disease (odds ratio 7.51 confidence interval 4.43-12.7) and intraoperative complications (odds ratio 2.97 confidence interval 1.38-6.42) were statistically significant predictors for final visual acuity of under 20/40 (p = < 0.001 and 0.005 respectively).
CONCLUSION: The outcome of PE was better than that of standard extracapsular cataract extraction in the same setting. However, since PE appeared to be used selectively, no clear advantage compared to extracapsular cataract extraction is evident in the period before the introduction of modern state-of-the-art PE-techniques.

Entities:  

Mesh:

Year:  1997        PMID: 9298419     DOI: 10.1023/a:1005886930452

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  13 in total

1.  Visual results and complications of phacoemulsification with intraocular lens implantation performed by ophthalmology residents.

Authors:  O A Cruz; G W Wallace; C A Gay; A Y Matoba; D D Koch
Journal:  Ophthalmology       Date:  1992-03       Impact factor: 12.079

2.  Incidence of vitreous loss among third-year residents performing phacoemulsification.

Authors:  R W Allinson; D C Metrikin; R G Fante
Journal:  Ophthalmology       Date:  1992-05       Impact factor: 12.079

3.  Learning phacoemulsification: the surgeon-in-training.

Authors:  H Tabandeh; B Smeets; M Teimory; H Seward
Journal:  Eye (Lond)       Date:  1994       Impact factor: 3.775

4.  Conversion to small-incision phacoemulsification: experience with the first 50 eyes.

Authors:  R B Prince; R L Tax; D H Miller
Journal:  J Cataract Refract Surg       Date:  1993-03       Impact factor: 3.351

5.  Safety during the transition to phacoemulsification: a survey.

Authors:  S E Navon; A P Adamis
Journal:  Int Ophthalmol Clin       Date:  1994

6.  Phacoemulsification during the learning curve: risk/benefit analysis.

Authors:  H C Seward; R Dalton; A Davis
Journal:  Eye (Lond)       Date:  1993       Impact factor: 3.775

7.  Phacoemulsification and intraocular lens implantation in patients with cataract. Experiences of a beginning 'phacoemulsification surgeon'.

Authors:  O O Pedersen
Journal:  Acta Ophthalmol (Copenh)       Date:  1990-02

8.  The National Cataract Surgery Survey: II. Clinical outcomes.

Authors:  P Desai
Journal:  Eye (Lond)       Date:  1993       Impact factor: 3.775

9.  Visual outcome and complications after cataract extraction in Saudi Arabia.

Authors:  M F al Faran
Journal:  Br J Ophthalmol       Date:  1990-03       Impact factor: 4.638

10.  Risk factors for intraoperative and early postoperative complications in extracapsular cataract surgery.

Authors:  P Lumme; L T Laatikainen
Journal:  Eur J Ophthalmol       Date:  1994 Jul-Sep       Impact factor: 1.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.